MARKET

BBOT

BBOT

BridgeBio Oncology Therapeutics, Inc
NASDAQ
7.89
+0.23
+3.00%
Closed 19:39 05/11 EDT
OPEN
7.85
PREV CLOSE
7.66
HIGH
8.31
LOW
7.70
VOLUME
468.11K
TURNOVER
0
52 WEEK HIGH
14.87
52 WEEK LOW
7.60
MARKET CAP
632.09M
P/E (TTM)
39.51
1D
5D
1M
3M
1Y
5Y
1D
This Arxis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 21h ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 22h ago
BridgeBio Oncology Price Target Announced at $23.00/Share by Canaccord Genuity
Dow Jones · 22h ago
Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23
Benzinga · 22h ago
Weekly Report: what happened at BBOT last week (0504-0508)?
Weekly Report · 1d ago
BridgeBio Oncology initiated with a Buy at Canaccord
TipRanks · 1d ago
Weekly Report: what happened at BBOT last week (0427-0501)?
Weekly Report · 05/04 10:32
BridgeBio Oncology Therapeutics’ Principal Accounting Officer Marc Cobo files Form 3 ownership statement
PUBT · 04/30 20:35
More
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Webull offers BridgeBio Oncology Therapeutics Inc stock information, including NASDAQ: BBOT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBOT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBOT stock methods without spending real money on the virtual paper trading platform.